JP6226889B2 - 新規抗マラリア薬 - Google Patents

新規抗マラリア薬 Download PDF

Info

Publication number
JP6226889B2
JP6226889B2 JP2014557157A JP2014557157A JP6226889B2 JP 6226889 B2 JP6226889 B2 JP 6226889B2 JP 2014557157 A JP2014557157 A JP 2014557157A JP 2014557157 A JP2014557157 A JP 2014557157A JP 6226889 B2 JP6226889 B2 JP 6226889B2
Authority
JP
Japan
Prior art keywords
phenyl
pyrazin
trifluoromethyl
amino
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014557157A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015507004A5 (OSRAM
JP2015507004A (ja
Inventor
ユニス、ヤセル
チベイル、ケリー
ジョン ウィッティ、マイケル
ジョン ウィッティ、マイケル
ウォーターソン、デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MMV Medicines for Malaria Venture
University of Cape Town
Original Assignee
MMV Medicines for Malaria Venture
University of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MMV Medicines for Malaria Venture, University of Cape Town filed Critical MMV Medicines for Malaria Venture
Publication of JP2015507004A publication Critical patent/JP2015507004A/ja
Publication of JP2015507004A5 publication Critical patent/JP2015507004A5/ja
Application granted granted Critical
Publication of JP6226889B2 publication Critical patent/JP6226889B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014557157A 2012-02-17 2013-02-15 新規抗マラリア薬 Expired - Fee Related JP6226889B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600324P 2012-02-17 2012-02-17
US61/600,324 2012-02-17
PCT/IB2013/051235 WO2013121387A1 (en) 2012-02-17 2013-02-15 Anti -malarial agents

Publications (3)

Publication Number Publication Date
JP2015507004A JP2015507004A (ja) 2015-03-05
JP2015507004A5 JP2015507004A5 (OSRAM) 2016-02-12
JP6226889B2 true JP6226889B2 (ja) 2017-11-08

Family

ID=48014134

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557157A Expired - Fee Related JP6226889B2 (ja) 2012-02-17 2013-02-15 新規抗マラリア薬

Country Status (20)

Country Link
US (1) US9266842B2 (OSRAM)
EP (1) EP2814820B1 (OSRAM)
JP (1) JP6226889B2 (OSRAM)
CN (1) CN104136426B (OSRAM)
BR (1) BR112014020212B1 (OSRAM)
CA (1) CA2864483A1 (OSRAM)
CY (1) CY1118074T1 (OSRAM)
DK (1) DK2814820T3 (OSRAM)
ES (1) ES2589283T3 (OSRAM)
HR (1) HRP20161237T1 (OSRAM)
HU (1) HUE029876T2 (OSRAM)
IN (1) IN2014MN01622A (OSRAM)
LT (1) LT2814820T (OSRAM)
ME (1) ME02535B (OSRAM)
PL (1) PL2814820T3 (OSRAM)
PT (1) PT2814820T (OSRAM)
SI (1) SI2814820T1 (OSRAM)
SM (1) SMT201600441B (OSRAM)
WO (1) WO2013121387A1 (OSRAM)
ZA (1) ZA201406786B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029876T2 (en) * 2012-02-17 2017-04-28 Univ Cape Town Anti-malaria agents
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017067881A1 (en) * 2015-10-19 2017-04-27 Glaxosmithkline Intellectual Property Development Limited Pyrazine compounds for use in the treatment of parasitic protozoal infections
CN111936488B (zh) * 2018-01-24 2023-06-27 葛兰素史克知识产权开发有限公司 用于治疗寄生虫感染的新颖化合物
CN112142715A (zh) * 2020-10-10 2020-12-29 鲁南制药集团股份有限公司 一种2-氨基-5-杂环基取代的吡嗪衍生物及其用途
JP2024543882A (ja) * 2021-11-23 2024-11-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 寄生性原生動物感染症に有用なピラジン化合物
CN119948032A (zh) 2022-08-09 2025-05-06 默克专利股份有限公司 呋喃并嘧啶衍生物
WO2024033280A1 (en) 2022-08-09 2024-02-15 Merck Patent Gmbh Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE497949T1 (de) * 2003-12-03 2011-02-15 Ym Biosciences Australia Pty Tubulininhibitoren
BRPI0713328A2 (pt) * 2006-06-22 2012-10-30 Biovitrum Ab derivados de piridina e pirazina como inibidores de cinase mnk
EP1900727A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
GB0625659D0 (en) * 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
ME02315B (me) * 2010-01-18 2016-06-20 Medicines For Malaria Venture Mmv Novi antimalarijski agensi
EP2569286B1 (en) * 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
KR20140014205A (ko) * 2011-03-04 2014-02-05 렉시컨 파마슈티컬스 인코퍼레이티드 Mst1 키나제 억제제 및 그의 사용 방법
HUE029876T2 (en) * 2012-02-17 2017-04-28 Univ Cape Town Anti-malaria agents

Also Published As

Publication number Publication date
DK2814820T3 (en) 2016-10-03
BR112014020212B1 (pt) 2021-11-23
BR112014020212A8 (pt) 2018-01-23
EP2814820B1 (en) 2016-07-20
SMT201600441B (it) 2017-01-10
ME02535B (me) 2017-02-20
SI2814820T1 (sl) 2016-10-28
US9266842B2 (en) 2016-02-23
EP2814820A1 (en) 2014-12-24
HUE029876T2 (en) 2017-04-28
HRP20161237T1 (hr) 2016-11-04
WO2013121387A1 (en) 2013-08-22
HK1202859A1 (en) 2015-10-09
CA2864483A1 (en) 2013-08-22
ES2589283T3 (es) 2016-11-11
JP2015507004A (ja) 2015-03-05
CN104136426B (zh) 2017-10-03
ZA201406786B (en) 2015-06-24
CY1118074T1 (el) 2017-06-28
PT2814820T (pt) 2016-10-25
PL2814820T3 (pl) 2017-01-31
LT2814820T (lt) 2016-10-25
IN2014MN01622A (OSRAM) 2015-05-15
US20150031682A1 (en) 2015-01-29
CN104136426A (zh) 2014-11-05

Similar Documents

Publication Publication Date Title
JP6226889B2 (ja) 新規抗マラリア薬
JP5735986B2 (ja) 新規抗マラリア剤
JP6622824B2 (ja) キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
CN104352492B (zh) 以芳基磺酰基衍生物作为有效成分的长链脂肪酸延长酶抑制剂
JP4523281B2 (ja) Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
CA2872110C (en) Nitrogenous heterocyclic derivatives and their application in drugs
CN112513021B (zh) RORγ拮抗剂及其在药物中的应用
WO2024146632A1 (zh) 一种四氢噻吩衍生物及其在医药上的应用
WO2024032661A1 (zh) Kif18a抑制剂及其用途
RS55998B1 (sr) Novi anti-malarijski agensi
WO2024099225A1 (zh) Ulk抑制剂
JP7624745B2 (ja) Ｔｒｐｖ４受容体リガンド
CN118339149A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
JP2019530712A (ja) 新規抗マラリア薬
CA3162585A1 (en) Anti-malarial agents
HK1202859B (en) Anti -malarial agents
RS55201B1 (sr) Antimalarijski agensi
JPH05117280A (ja) アミノ酸置換チアゼトキノリン−３−カルボン酸誘導体
CN106065018A (zh) 取代的吲哚化合物及其使用方法和用途
JP2023520816A (ja) 新規の抗マラリア薬
HK1175472B (en) New anti-malarial agents
JPH03232864A (ja) 三置換ピペラジン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171010

R150 Certificate of patent or registration of utility model

Ref document number: 6226889

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees